BRIEF-Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical Development

Reuters11-07

BRIEF-Coeptis <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical Development

Nov 7 (Reuters) - Coeptis Therapeutics Holdings Inc COEP.O:

COEPTIS THERAPEUTICS ANNOUNCES PHASE 1 DATA ON DVX201 FOR COVID-19 TREATMENT HAS BEEN ACCEPTED FOR PUBLICATION IN MOLECULAR THERAPY METHODS AND CLINICAL DEVELOPMENT

Source text: ID:nPn6yjmXXa

Further company coverage: COEP.O

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481999904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481999904","market":"us","top_or_hot":-1,"title":"BRIEF-Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Coeptis <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical Development</title></head><body><p><span>Nov 7 (Reuters)</span><span> - </span>Coeptis Therapeutics Holdings Inc <span>COEP.O</span>:</p><ul><li><p>COEPTIS THERAPEUTICS ANNOUNCES PHASE 1 DATA ON DVX201 FOR COVID-19 TREATMENT HAS BEEN ACCEPTED FOR PUBLICATION IN MOLECULAR THERAPY METHODS AND CLINICAL DEVELOPMENT</p></li></ul><p>Source text: <span>ID:nPn6yjmXXa</span></p><p>Further company coverage: <span>COEP.O</span></p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 21:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME0WK:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical DevelopmentNov 7 (Reuters) - Coeptis ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME0WK:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME0WK:1","article_id":"2481999904","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481999904","pubTimestamp":1730984903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical DevelopmentNov 7 (Reuters) - Coeptis Ther","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","COEP":"COEPTIS THERAPEUTICS HOLDINGS INC"},"translate_title":"简介-Coeptis Therapeutics宣布DVX201用于Covid-19治疗的1期数据已被接受发表在《分子治疗方法和临床开发》上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COEP":0.9},"content_text":"BRIEF-Coeptis Therapeutics Announces Phase 1 Data On DVX201 For Covid-19 Treatment Has Been Accepted For Publication In Molecular Therapy Methods And Clinical DevelopmentNov 7 (Reuters) - Coeptis Therapeutics Holdings Inc COEP.O:COEPTIS THERAPEUTICS ANNOUNCES PHASE 1 DATA ON DVX201 FOR COVID-19 TREATMENT HAS BEEN ACCEPTED FOR PUBLICATION IN MOLECULAR THERAPY METHODS AND CLINICAL DEVELOPMENTSource text: ID:nPn6yjmXXaFurther company coverage: COEP.O (Reuters.Briefs@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481999904"}